Literature DB >> 7772617

Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression.

M Maes1, H Y Meltzer, P Buckley, E Bosmans.   

Abstract

This study was carried out to examine some components of in vivo immune function in major depression and schizophrenia. Toward this end, plasma concentrations of interleukin-1 beta (IL-1 beta) and IL-6, soluble IL-2 receptor (sIL-2R), and transferrin receptor (TfR) were measured in 28 normal controls, 11 schizophrenics and 13 major-depressed patients. Schizophrenic and major-depressed patients showed significantly higher plasma sIL-2R and TfR than normal controls. There was a trend toward higher plasma IL-6 in the psychiatric patients, and particularly in schizophrenic patients, than in normal volunteers. In normal controls and in the total study group, there were highly significant and positive correlations between plasma TfR and sIL-2R concentrations. It is suggested that schizophrenia and major depression are characterized by immune disorders that may indicate activation of cell-mediated immunity such as T-cell activation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7772617     DOI: 10.1007/bf02190412

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  33 in total

1.  Elevated levels of acute phase plasma proteins in major depression.

Authors:  P R Joyce; C R Hawes; R T Mulder; J D Sellman; D A Wilson; D R Boswell
Journal:  Biol Psychiatry       Date:  1992-12-01       Impact factor: 13.382

2.  A comprehensive macrophage-T-lymphocyte theory of schizophrenia.

Authors:  R S Smith
Journal:  Med Hypotheses       Date:  1992-11       Impact factor: 1.538

3.  Increased serum interleukin 2 receptor concentration in schizophrenic and brain-damaged subjects.

Authors:  R Ganguli; B S Rabin
Journal:  Arch Gen Psychiatry       Date:  1989-03

4.  Are there antibodies against brain in sera from schizophrenic patients? Review and prospectus.

Authors:  L E DeLisi; R J Weber; C B Pert
Journal:  Biol Psychiatry       Date:  1985-01       Impact factor: 13.382

5.  Is schizophrenia caused by excessive production of interleukin-2 and interleukin-2 receptors by gastrointestinal lymphocytes?

Authors:  R S Smith
Journal:  Med Hypotheses       Date:  1991-03       Impact factor: 1.538

6.  Concentration and microheterogeneity glycophorms of alpha-1-acid glycoprotein in major depressive disorder.

Authors:  A Sluzewska; J K Rybakowski; M Sobieska; K Wiktorowicz
Journal:  J Affect Disord       Date:  1996-07-08       Impact factor: 4.839

7.  The soluble transferrin receptor: biological aspects and clinical usefulness as quantitative measure of erythropoiesis.

Authors:  Y Beguin
Journal:  Haematologica       Date:  1992 Jan-Feb       Impact factor: 9.941

8.  The macrophage theory of depression.

Authors:  R S Smith
Journal:  Med Hypotheses       Date:  1991-08       Impact factor: 1.538

9.  Altered interleukin-2 production in schizophrenia: association between clinical state and autoantibody production.

Authors:  R Ganguli; J S Brar; W Solomon; K N Chengappa; B S Rabin
Journal:  Psychiatry Res       Date:  1992-11       Impact factor: 3.222

10.  Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation.

Authors:  D De Groote; P F Zangerle; Y Gevaert; M F Fassotte; Y Beguin; F Noizat-Pirenne; J Pirenne; R Gathy; M Lopez; I Dehart
Journal:  Cytokine       Date:  1992-05       Impact factor: 3.861

View more
  16 in total

1.  Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid.

Authors:  Buranee Kanchanatawan; Sunee Sirivichayakul; Kiat Ruxrungtham; André F Carvalho; Michel Geffard; Heidi Ormstad; George Anderson; Michael Maes
Journal:  Mol Neurobiol       Date:  2017-02-08       Impact factor: 5.590

2.  Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects.

Authors:  Brian J Miller; Peter Buckley; Wesley Seabolt; Andrew Mellor; Brian Kirkpatrick
Journal:  Biol Psychiatry       Date:  2011-06-08       Impact factor: 13.382

3.  Phagocytosis and killing of Staphylococcus aureus: effects of stress and depression in children.

Authors:  J A Bartlett; M K Demetrikopoulos; S J Schleifer; S E Keller
Journal:  Clin Diagn Lab Immunol       Date:  1997-05

Review 4.  Inflammatory biomarkers and depression.

Authors:  Norbert Müller; Aye-Mu Myint; Markus J Schwarz
Journal:  Neurotox Res       Date:  2010-07-24       Impact factor: 3.911

Review 5.  The neurobiology of apolipoproteins in psychiatric disorders.

Authors:  J Gregor Sutcliffe; Elizabeth A Thomas
Journal:  Mol Neurobiol       Date:  2002 Oct-Dec       Impact factor: 5.590

Review 6.  [Immunological aspects of depressive disorders].

Authors:  N Müller; M J Schwarz
Journal:  Nervenarzt       Date:  2007-11       Impact factor: 1.214

Review 7.  A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders.

Authors:  Norbert Müller; Markus J Schwarz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06       Impact factor: 5.270

Review 8.  [Cytokine network in patients with schizophrenia and its significance for the pathophysiology of the illness].

Authors:  A Schuld; D Hinze-Selch; Th Pollmächer
Journal:  Nervenarzt       Date:  2004-03       Impact factor: 1.214

9.  Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: implications for genesis of neurodevelopmental disorders.

Authors:  S Hossein Fatemi; Teri J Reutiman; Timothy D Folsom; Hao Huang; Kenichi Oishi; Susumu Mori; Donald F Smee; David A Pearce; Christine Winter; Reinhard Sohr; Georg Juckel
Journal:  Schizophr Res       Date:  2008-01-09       Impact factor: 4.939

10.  Inflammatory and Oxidative Pathways Are New Drug Targets in Multiple Episode Schizophrenia and Leaky Gut, Klebsiella pneumoniae, and C1q Immune Complexes Are Additional Drug Targets in First Episode Schizophrenia.

Authors:  Michael Maes; Aristo Vojdani; Sunee Sirivichayakul; Decio S Barbosa; Buranee Kanchanatawan
Journal:  Mol Neurobiol       Date:  2021-03-06       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.